نتایج جستجو برای: warfarin venous thromboembolism

تعداد نتایج: 85981  

2017
Clive Kearon Michael J Kovacs

Some of Paul Kyrle and Sabine Eichinger’s recommendations about long-term prevention of recurrent venous thromboembolism (Mar 26, p 1163) do not seem to be consistent with the results of randomised trials. First, they recommend stopping anticoagulant therapy for unprovoked (spontaneous) proximal deep vein thrombosis after 3 or 6 months, even though the two trials that compared this practice wit...

Journal: :Blood 2011
Inna Y Gong Rommel G Tirona Ute I Schwarz Natalie Crown George K Dresser Samantha Larue Nicole Langlois Alejandro Lazo-Langner Guangyong Zou Dan M Roden C Michael Stein Marc Rodger Marc Carrier Melissa Forgie Philip S Wells Richard B Kim

Single-nucleotide polymorphisms in genes that affect warfarin metabolism (cytochrome P450 2C9 gene, CYP2C9) and response (vitamin K epoxide reductase complex 1 gene, VKORC1) have an important influence on warfarin therapy, particularly during initiation; however, there is a lack of consensus regarding the optimal pharmacogenetics-based initiation strategy. We conducted a prospective cohort stud...

Journal: :JAMA 2015
Francis Couturaud Olivier Sanchez Gilles Pernod Patrick Mismetti Patrick Jego Elisabeth Duhamel Karine Provost Claire Bal dit Sollier Emilie Presles Philippe Castellant Florence Parent Pierre-Yves Salaun Luc Bressollette Michel Nonent Philippe Lorillon Philippe Girard Karine Lacut Marie Guégan Jean-Luc Bosson Silvy Laporte Christophe Leroyer Hervé Décousus Guy Meyer Dominique Mottier

IMPORTANCE The optimal duration of anticoagulation after a first episode of unprovoked pulmonary embolism is uncertain. OBJECTIVES To determine the benefits and harms of an additional 18-month treatment with warfarin vs placebo, after an initial 6-month nonrandomized treatment period on a vitamin K antagonist. DESIGN, SETTING, AND PARTICIPANTS Randomized, double-blind trial (treatment perio...

Journal: :BMJ supportive & palliative care 2012
Simon Noble Miriam J Johnson

The management of venous thromboembolism in the cancer population is clearly established. Low molecular weight heparin has a greater efficacy than warfarin in the treatment of cancer-associated thrombosis and is recommended as the preferred therapy. However, the evidence informing these recommendations excluded patients with poor prognosis or performance status, thrombocytopenia, bleeding or br...

2008
K.M.J. Brose A.Y.Y. Lee

Patients with cancer are at high risk to develop venous thromboembolism, and they are also more likely to develop complications from anticoagulant treatment. Because little research has focused on the oncology population to date, the optimal methods of prophylaxis and treatment remain uncertain in some clinical situations. Currently, low molecular weight heparin and warfarin are the most freque...

Journal: :The Canadian journal of hospital pharmacy 2016
May Choi Marcy Mintz Duane Bates

For decades, warfarin has been the primary anticoagulant for the primary and secondary prevention of venous and arterial thromboembolic events. There is an extensive amount of literature that has contributed to the understanding of the complex pharmacokinetics and pharmacodynamics of warfarin, its interactions with drugs and other compounds, its antithrombotic effects, and the risks associated ...

2013
Tsuyoshi Kaneko Sary F. Aranki

Implantation of prosthetic valve requires consideration for anticoagulation. The current guideline recommends warfarin on all mechanical valves. Dabigatran is the new generation anticoagulation medication which is taken orally and does not require frequent monitoring. This drug is approved for treatment for atrial fibrillation and venous thromboembolism, but the latest large trial showed that t...

2010
Patrick P Kneeland Margaret C Fang

Warfarin therapy reduces morbidity and mortality related to thromboembolism. Yet adherence to long-term warfarin therapy remains challenging due to the risks of anticoagulant-associated complications and the burden of monitoring. The aim of this paper is to review determinants of adherence and persistence on long-term anticoagulant therapy for atrial fibrillation and venous thromboembolism. We ...

Journal: :Hematology. American Society of Hematology. Education Program 2003
Andrew I Schafer Mark N Levine Barbara A Konkle Clive Kearon

Hematologists are increasingly involved in the diagnosis and management of patients with venous and arterial thromboembolic disorders. There have been major advances in recent years in our understanding of the central role of hypercoagulability in the pathogenesis of thrombosis. This has led to new approaches to the diagnosis of patients at risk for thrombosis and the development of more ration...

2009
Andrew D Blann Chee W Khoo

As the risk factors for thrombosis are becoming better understood, so is the need for anticoagulation. The inherent difficulties with warfarin are such that a low-molecular-weight heparin (LMWH) is often the key therapeutic. However, there are several different species of LMWH available to the practitioner, which leads to the need for an objective guide. New agents are coming onto the marketpla...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید